跳至主要内容
临床试验/NCT03432234
NCT03432234Unknown不适用

Respiratory Microbiome and COPD Exacerbations

Corporacion Parc Tauli6 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2016年3月7日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
120
试验地点
6
主要终点
Respiratory Microbiome in COPD patients with FE and NE.

研究概览

简要总结

The global objective of this coordinated project is to test the following hypotheses: 1) the lung microbiome in chronic obstructive pulmonary disease (COPD) is different in patients suffering from frequent exacerbations (FE) compared those who do not (NE ); 2) The microbial profile of patients with FE is associated with a different local and systemic inflammatory pattern; and 3) the inflammatory and immune characteristics of COPD are modulated by the intestinal microbiome.

The project is based on bronchoalveolar lavage (BAL) for sampling lung microbiome, and includes analysis of regional variability (intrapulmonary) and temporal variability. The project will also assess the correlation between BAL samples obtained from the proximal airway (oral cavity, oropharynx and sputum), and the representation of lung microbiome in them. A cohort of COPD patients (n = 50 FE; n = 50 NE) and healthy subjects (n= 30), matched by age, sex and tobacco consumption. Respiratory secretion samples will be collected in clinical stability samples, with resampling in a quarter of the participants at 6-9 months. Coordinator Project: Bacterial and fungal microbiota will be determined by 16S rRNA and ITS amplification and sequencing. Virome and functional metagenomics will be analyzed in a quarter of the participants. Subprojects: Regional variability in the lung, local and systemic inflammatory response, and the relationship between the intestinal microbiome and inflammatory and clinical characteristics of the disease will be determined. The integration of the results will be performed using network medicine methodologies. The results of this project will help to understand the pathogenesis of COPD and its exacerbations with the final aim to identify new therapeutic targets.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Spirometry: FEV1/FVC < 70%; FEV1 between 50 and 80% predicted (GOLD II/III)
  • Clinical Stability (no therapeutic change and/or use of antibiotics) during 8 weeks. - The treatment received will be registered for post-hoc studies stratified by this condition.

排除标准

  • Drug addiction, alcohol abuse,
  • Use of long-term oral or nebulised antibiotic therapy.
  • History of allergies, asthma or other chronic respiratory disease, sanitary worker, working exposure to dust or fumes.
  • Other diseases: Severe cardiovascular, neurological, psychiatric, renal, hepatic or gastrointestinal , that might interfere with the daily life activities.

结局指标

主要结局

Respiratory Microbiome in COPD patients with FE and NE.

时间窗: 7 days

Respiratory Microbiome composition will be determined by using metagenomic aproaches.

次要结局

  • Bacteria related to pulmonary and systemic inflamatory factors (FE vs NE)(7 days)
  • Longitudinal variability of respiratory microbiome in COPD patients (FE vs NE).(12 months)
  • Inmunological response of lung epithelial cells COPD patients after an infectious and inflammatory stimuli(7 days)

研究者

发起方
Corporacion Parc Tauli
申办方类型
Other
责任方
Principal Investigator
主要研究者

Eduard Monsó-Molas

Head of Respiratory Medicine Department

Corporacion Parc Tauli

研究点 (6)

Loading locations...

相似试验